Navigation Links
Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
Date:1/8/2009

SAN DIEGO, Jan. 8 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX) today announced that the first of four Phase 3 trials of its lead investigational product Contrave(R) (naltrexone sustained release (SR)/bupropion SR) met its co-primary and key secondary endpoints, showing a significant reduction in body weight, improvements in markers of cardiovascular risk and reductions in selected food craving measures.

In this trial, which included an intensive diet and exercise behavior modification regimen, obese patients treated with Contrave, based on intent-to-treat (ITT) and completer analyses, lost an average of 20.3 pounds to 25.0 pounds, or 9.3% to 11.5% of their baseline body weight, versus 11.0 pounds to 16.0 pounds, or 5.1% to 7.3% of baseline body weight, for patients treated with placebo. In addition, in the categorical weight reduction analysis, the percentage of patients who lost greater than or equal to 10% of their body weight was 20.2% in the placebo group compared to 41.5% in the Contrave group. We believe these results satisfy the categorical FDA efficacy benchmark for clinically significant weight loss. All of these findings were highly statistically significant (p<0.001).

Contrave was generally well tolerated by patients. The overall safety profile of Contrave was consistent with its individual components, naltrexone and bupropion, two drugs that have been used separately in patients for over 20 years. Treatment with Contrave was not associated with increases in symptoms of depression, suicidality or worsening of mean blood pressure.

"The results of this trial indicate that additional, clinically significant weight loss can be achieved when Contrave is added to a rigorous program of diet and exercise," said Eduardo Dunayevich, Chief Medical Officer, Orexige
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
2. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
3. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
4. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
5. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
6. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
7. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
8. InteKrin Therapeutics to Present at the 27th Annual JP Morgan Healthcare Conference on Tuesday, January 13
9. Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
10. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
11. Cell Therapeutics Announces Receipt of NASDAQ Panel Decision to Transfer to NASDAQ Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... 2014 Five American winners will ... Maktoum Awards for Medical Sciences", in its 8 th ... Emirates , on 15 December 2014. ... The Carter Center which won the Hamdan Award for ... numerous programs that aim to improve health and promote ...
(Date:11/24/2014)... 23, 2014 One of the most extensive, ... and photonics is now available to high school and junior ... SPIE, the international society for optics and photonics , ... SPIE Digital Library available to high schools for ... technologies are integral to all areas of life in today’s ...
(Date:11/24/2014)... Senior Vice President, General Manager ... skills, business acumen Elsevier , a ... and services, congratulates Diane Bartoli , Senior Vice ... Elsevier Clinical Solutions, for being recognized in the 13 ... issue of Profiles in Diversity Journal ® ...
(Date:11/22/2014)... November 21, 2014 CannLabs, Inc. ... based analytics and scientific testing methodologies relating to cannabis, ... a $750,000 line of credit from an existing stockholder ... to have secured this commitment from one of our ... of CannLabs. “This capital will help accelerate our planned ...
Breaking Biology Technology:Five US Winners Among Recipients of Hamdan Medical Awards 2SPIE Digital Library Now Available to High Schools, Two-Year Colleges at No or Low Cost 2Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 2Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 3CannLabs Secures $750,000 Line Of Credit 2
... , , , , ... FuGENE 6 Transfection Reagent in Vector-based shRNA Experiments , ... RNA interference induced by siRNAs or shRNAs allows reliable down-regulation of ... into cells are used directly for transient gene silencing, ,vectors that encode for the ...
... , , , , , ... a powerful genome-wide expression profiling technology. Agencourt offers , ... libraries to make SAGE technology more accessible to researchers. Agencourt's , ... Rapid turnaround , , ...
... , Agencourt offers high quality end sequencing for BACs, ... per day. The key features of our end, sequencing service are:, ... Increased linkage rates , ... , , ...
Cached Biology Technology:SAGE & LONGSAGE SEQUENCING 2END SEQUENCING 2
(Date:11/18/2014)... 18, 2014   EyeLock Inc. , a ... MorphoTrust USA (Safran), a leading U.S. ... a strategic partnership to offer comprehensive biometric identity ... (MVA), airport screening and financial services markets. ... serves consumers through a nationwide network of 1,100 ...
(Date:11/10/2014)... began appearing on U.S. store shelves in early 2010, ... since. The small packets can be tossed into a ... liquid or powder. The convenience, though, has come with ... researchers at Nationwide Children,s Hospital found that from 2012 ... 17,230 children younger than 6 years of age swallowing, ...
(Date:11/6/2014)... paper from a team of Florida State University biologists ... could adapt to and survive environmental swings such as ... latest issue of the journal The Plant Cell ... DNA and proteins) is organized in a cell and ... are turned on and others are turned off. , ...
Breaking Biology News(10 mins):EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Study finds laundry detergent pods, serious poisoning risk for children 2Maize analysis yields whole new world of genetic science 2
... A more flexible approach to the expansion of protected ... the same budget according to a new paper in ... Richard Fuller of the CSIRO Climate Adaptation Flagship and ... money "we could dramatically improve the performance of protected ...
... Researchers at North Carolina State University have developed ... woody plants that significantly reduces the waste that ... is a significant step toward creating a commercially ... makes the process more efficient and less expensive," ...
... are reporting dramatic new real-world evidence supporting the idea ... disease. It appears in a new study showing a ... of stored drinking water, and health in households in ... ACS, Environmental Science & Technology , a semi-monthly ...
Cached Biology News:Conserving nature and dollars: Delivering cost-effective biodiversity protection 2New technique improves efficiency of biofuel production 2
... Wellpro 384, compatible ... automated liquid handling system ... quickly and accurately prepares ... dilutions. The Wellpro ...
...
...
Multidrop DW is a high-speed automated dispenser for Deep Well plates, 1.1 ml test tubes and 96-well plates. Designed for accuracy and precision, the Multidrop DW dispenses up to eight different reag...
Biology Products: